HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Design, synthesis, anticonvulsant, and antiarrhythmic properties of novel N-Mannich base and amide derivatives of β-tetralinohydantoin.

AbstractBACKGROUND:
5,5-Diphenylhydantoin (Phenytoin) is a well-known anticonvulsant and antiarrhythmic drug which may cause unwanted side effects. In order to avoid the adverse effects of phenytoin, especially on the central nervous and cardiovascular systems, two small series of amine derivatives (Mannich bases) and amide ones were designed containing β-tetralinohydantoin system. In preliminary studies, some of arylpiperazinylmethyl derivatives with a β-tetralinohydantoin moiety were effective in screening anticonvulsant tests in mice.
METHODS:
These new amine and amide derivatives of β-tetralinohydantoin were evaluated in standard anticonvulsant screens (maximal electroshock (MES) or pentylenetetrazole (scPTZ) seizure tests) and their neurotoxicity was assessed in standardized rotarod tests. Additionally, due to structural features (a hydantoin ring), influence on antiarrhythmic activity, electrocardiogram components and blood pressure was tested in rats.
RESULTS:
The new N-Mannich bases were effective in maximal electroshock or pentylenetetrazole seizures screens; and the most interesting compound 4 (1-{[4-(1-phenyethyl)-piperazin-1-yl]methyl}-3',4'-dihydro-1'H,2H,5H-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione) displayed anticonvulsant activity in both the aforementioned tests. Furthermore, compound 6, an amide derivative of β-tetralinohydantoin, displayed significant antiarrhythmic activity in a barium chloride-induced arrhythmia model (ED50 16.3mg/kg), but it was devoid of anticonvulsant protection. None of the tested compounds affected the electrocardiogram components or blood pressure in normotensive rats.
CONCLUSION:
All new N-Mannich bases containing the β-tetralinohydantoin system and 1-phenylalkylpiperazine were classified to Anticonvulsant Screening Program 1st class. In contrast, our results suggested that the introduction of an amide bond in the alkyl side chain of the β-tetralinohydantoin system abolished the anticonvulsant activity, but not the antiarrhythmic one. However, further studies are required for a definitive conclusion.
AuthorsAnna Czopek, Hanna Byrtus, Agnieszka Zagórska, Agata Siwek, Grzegorz Kazek, Marek Bednarski, Jacek Sapa, Maciej Pawłowski
JournalPharmacological reports : PR (Pharmacol Rep) Vol. 68 Issue 5 Pg. 886-93 (Oct 2016) ISSN: 2299-5684 [Electronic] Switzerland
PMID27351944 (Publication Type: Journal Article)
CopyrightCopyright © 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
Chemical References
  • Amides
  • Anti-Arrhythmia Agents
  • Anticonvulsants
  • Mannich Bases
  • Phenytoin
  • Pentylenetetrazole
Topics
  • Amides (chemistry)
  • Animals
  • Anti-Arrhythmia Agents (adverse effects, chemistry, pharmacology)
  • Anticonvulsants (adverse effects, chemistry, pharmacology)
  • Disease Models, Animal
  • Drug Design
  • Electroshock (methods)
  • Male
  • Mannich Bases (chemistry)
  • Neurotoxicity Syndromes (etiology)
  • Pentylenetetrazole (chemistry)
  • Phenytoin (chemistry)
  • Rats
  • Rats, Sprague-Dawley
  • Rotarod Performance Test (methods)
  • Seizures (drug therapy)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: